Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1993-6-4
|
| pubmed:abstractText |
The purpose is twofold: (1) to identify the malignant glioma patients treated in a trial of hyperfractionated radiotherapy (RT) and carmustine (BCNU) who may have been eligible for a stereotactic radiosurgery (SRS) boost; and (2) to compare survival of such patients with that of those considered SRS-ineligible.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
857-62
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8487050-Carmustine,
pubmed-meshheading:8487050-Combined Modality Therapy,
pubmed-meshheading:8487050-Female,
pubmed-meshheading:8487050-Glioma,
pubmed-meshheading:8487050-Humans,
pubmed-meshheading:8487050-Male,
pubmed-meshheading:8487050-Middle Aged,
pubmed-meshheading:8487050-Proportional Hazards Models,
pubmed-meshheading:8487050-Radiosurgery,
pubmed-meshheading:8487050-Radiotherapy Dosage
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
|
| pubmed:affiliation |
Fox Chase Cancer Center, Philadelphia, PA 19111.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|